Matches
From your records, pre-screened. Add internal candidates to a study, or refer external ones out.
RM
R.M.
54· Female
Your study
Major depressive disorder, partial response to sertraline. Coming in Thu for a routine follow-up.
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
NCT07564414
DSM-5-TR MDD in a current episode · Current episode duration within the 6-week to 24-month window
Upcoming visit · Thu 10:30
Likely eligible
DO
D.O.
47· Male
Your study
Recurrent MDD with persistent insomnia, on escitalopram with partial benefit. Seen last month.
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
NCT07219966
MDD without psychotic features · Reports clinically significant insomnia
Problem list · seen 3w ago
Likely eligible
DO
D.O.
47· Male
Your study
Recurrent MDD with persistent insomnia, on escitalopram with partial benefit. Seen last month.
Elismetrep (K-304) for the Acute Treatment of Migraine
NCT07645924
MDD without psychotic features · Reports clinically significant insomnia
Problem list · seen 3w ago
Likely eligible
EC
E.C.
72· Female
Partner site
Mild cognitive impairment, MMSE 25, family history of Alzheimer's. Followed in clinic.
Anti-Amyloid Infusion in Early Alzheimer's Disease
Sunnybrook Health Sciences Centre · Toronto, ON
MCI with documented memory decline · Age within 55-80 window
Problem list
Likely eligible
EC
E.C.
72· Female
Partner site
Mild cognitive impairment, MMSE 25, family history of Alzheimer's. Followed in clinic.
Anti-Amyloid Infusion in Early Alzheimer's Disease
Sunnybrook Health Sciences Centre · Toronto, ON
MCI with documented memory decline · Age within 55-80 window
Problem list
Likely eligible
AL
A.L.
43· Female
Your study
Moderate MDD, MADRS ~24, no bipolar history. New patient this week.
Azetukalner Open-Label Extension in Major Depressive Disorder (X-NOVA-OLE)
NCT06922110
Current MDE, moderate severity · No bipolar/psychotic history
New this week
Likely eligible
TW
T.W.
39· Male
Partner site
Moderate-to-severe plaque psoriasis, ~12% BSA, failed two topicals.
Once-Daily Oral Therapy for Moderate-to-Severe Plaque Psoriasis
Toronto Dermatology Research · Toronto, ON
BSA ≥10% meets severity threshold · Failed prior topical therapy
Upcoming visit · next week
Likely eligible
TW
T.W.
39· Male
Partner site
Moderate-to-severe plaque psoriasis, ~12% BSA, failed two topicals.
Once-Daily Oral Therapy for Moderate-to-Severe Plaque Psoriasis
Toronto Dermatology Research · Toronto, ON
BSA ≥10% meets severity threshold · Failed prior topical therapy
Upcoming visit · next week
Likely eligible
PR
P.R.
50· Female
Your study
Migraine with aura, ~6 attacks/month. Flagged at a recent visit.
Ubrogepant for Menstrual Migraine
NCT06417775
Over 1-year migraine history (IHS) · 6 attacks/month is in range
Recent visit
Likely eligible
PR
P.R.
50· Female
Your study
Migraine with aura, ~6 attacks/month. Flagged at a recent visit.
Ubrogepant for Menstrual Migraine
NCT06417775
Over 1-year migraine history (IHS) · 6 attacks/month is in range
Recent visit
Likely eligible
SK
S.K.
61· Female
Your study
Episodic migraine, roughly 5 moderate/severe attacks per month, no aura.
Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer.
NCT07216742
Over 1-year migraine history (IHS) · Attack frequency in range
Upcoming visit · next Tue
Possible
SK
S.K.
61· Female
Your study
Episodic migraine, roughly 5 moderate/severe attacks per month, no aura.
Seltorexant Monotherapy in Major Depressive Disorder
NCT07573176
Over 1-year migraine history (IHS) · Attack frequency in range
Upcoming visit · next Tue
Possible
JT
J.T.
58· Male
Your study
Treatment-resistant depression; failed 3 adequate antidepressant trials this episode.
Azetukalner vs Placebo in Major Depressive Disorder (X-NOVA3)
NCT07076407
MDD without psychotic features · Multiple prior treatment failures
Problem list
Possible
JT
J.T.
58· Male
Your study
Treatment-resistant depression; failed 3 adequate antidepressant trials this episode.
Azetukalner vs Placebo in Major Depressive Disorder (X-NOVA3)
NCT07076407
MDD without psychotic features · Multiple prior treatment failures
Problem list
Possible
CN
C.N.
63· Male
Your study
Depressive episode, but a note of possible past hypomania in the chart.
COMP360 Psilocybin in Treatment-Resistant Depression
NCT05711940
Current depressive episode documented
Upcoming visit · Mon
Possible
CN
C.N.
63· Male
Your study
Depressive episode, but a note of possible past hypomania in the chart.
COMP360 Psilocybin in Treatment-Resistant Depression
NCT05711940
Current depressive episode documented
Upcoming visit · Mon
Possible
MP
M.P.
66· Male
Your study
MDD, prior MI (2019), coming in for a medication review.
Adjunctive Seltorexant in MDD With Insomnia Symptoms
NCT06559306
Meets criteria for a current depressive episode
Upcoming visit · Fri
Possible
MP
M.P.
66· Male
Your study
MDD, prior MI (2019), coming in for a medication review.
Adjunctive Seltorexant in MDD With Insomnia Symptoms
NCT06559306
Meets criteria for a current depressive episode
Upcoming visit · Fri
Possible
RM
R.M.
54· Female
Your study
Passed
Major depressive disorder, partial response to sertraline. Coming in Thu for a routine follow-up.
Elismetrep (K-304) Long-Term Safety in Acute Migraine
NCT07674654
DSM-5-TR MDD in a current episode · Current episode duration within the 6-week to 24-month window
Upcoming visit · Thu 10:30
Likely eligible
WG
W.G.
56· Male
Your study
Added to study
Treatment-resistant depression, MADRS 28, failed two adequate antidepressant trials.
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
NCT07219966
MADRS 28 (moderate-to-severe) · Two documented antidepressant failures
Psychiatry referral
Likely eligible
WG
W.G.
56· Male
Your study
Added to study
Treatment-resistant depression, MADRS 28, failed two adequate antidepressant trials.
Elismetrep (K-304) for the Acute Treatment of Migraine
NCT07645924
MADRS 28 (moderate-to-severe) · Two documented antidepressant failures
Psychiatry referral
Likely eligible
AL
A.L.
43· Female
Your study
Added to study
Moderate MDD, MADRS ~24, no bipolar history. New patient this week.
Azetukalner Open-Label Extension in Major Depressive Disorder (X-NOVA-OLE)
NCT06922110
Current MDE, moderate severity · No bipolar/psychotic history
New this week
Likely eligible
HB
H.B.
41· Female
Your study
Passed
Episodic migraine, ~4 attacks/month, on no preventive therapy. New patient.
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
NCT07564414
Over 1-year migraine history · Attack frequency within 2-10/month
New patient this week
Likely eligible
HB
H.B.
41· Female
Your study
Passed
Episodic migraine, ~4 attacks/month, on no preventive therapy. New patient.
Elismetrep (K-304) Long-Term Safety in Acute Migraine
NCT07674654
Over 1-year migraine history · Attack frequency within 2-10/month
New patient this week
Likely eligible
GR
G.R.
45· Female
Partner site
Referral sent
Crohn's disease, moderate activity despite azathioprine. Recent flare.
Investigational Biologic for Moderate-to-Severe Crohn's Disease
Mount Sinai IBD Centre · Toronto, ON
Confirmed Crohn's, moderate activity · Inadequate response to immunomodulator
Problem list · flare 2w ago
Possible
GR
G.R.
45· Female
Partner site
Referral sent
Crohn's disease, moderate activity despite azathioprine. Recent flare.
Investigational Biologic for Moderate-to-Severe Crohn's Disease
Mount Sinai IBD Centre · Toronto, ON
Confirmed Crohn's, moderate activity · Inadequate response to immunomodulator
Problem list · flare 2w ago
Possible